What's in London Health Sciences Centre's pipeline?

London Health Sciences Centre has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with London Health Sciences Centre's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/london-health-sciences-centre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

London Health Sciences Centre — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

London Health Sciences Centre pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Mycophenolate to sirolimus switch	Mycophenolate to sirolimus switch	marketed	Immunosuppressant combination therapy	mTOR (sirolimus component); IMPDH (mycophenolate component being replaced)	Immunology / Transplantation

Therapeutic area mix

Immunology / Transplantation · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for London Health Sciences Centre:

Cite this brief

Drug Landscape (2026). London Health Sciences Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/london-health-sciences-centre. Accessed 2026-05-16.